Navigation Links
Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009

CHADDS FORD, Pa., Aug. 31 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it will present at the Thomas Weisel Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer of Endo, will review the company's products and development programs.

The presentation will be webcast live and can be accessed from Endo's website at under the investors section.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM((R)), a topical patch to relieve the pain of postherpetic neuralgia; Percocet((R)) and Percodan((R)) tablets for the relief of moderate-to-moderately severe pain; FROVA((R)) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA((R) )tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA((R)) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren((R) )Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; SANCTURA((R)) and its XR version for treatment of overactive bladder; VANTAS((R)) for the palliative treatment of advanced prostate cancer; and SUPPRELIN((R)) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
2. Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs
3. Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
4. AUDIO from Medialink, Boehringer Ingelheim Pharmaceuticals, Inc. & Pfizer Inc.: Coping with Chronic Obstructive Pulmonary Disease (COPD)
5. Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals
6. Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready-to-Use IV Bags
7. Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
8. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
9. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Baird Healthcare Investor Conferences on September 9 and September 10, 2009
11. Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology: